Glatiramer acetate (GA) introduced in the therapy of multiple sclerosis has been shown to induce CD8+ Ts, which seem to recognize GA on the cell surface and directly kill CD4+ T cells in a HLA-E-dependent manner (76). This evidence concerns the gene CD8A and multiple sclerosis.